Syntic Life Reports Positive Cellular-Rejuvenation Results in Mouse Models

FOR IMMEDIATE RELEASE

Preclinical findings show partial epigenetic reprogramming can move cells toward a younger biological state, supporting continued advancement toward IND-enabling studies.

California, United States — June 30, 2026 — Syntic Life, a biotechnology company developing gene therapies that target the underlying biology of aging, today reported positive preclinical results demonstrating cellular rejuvenation in mouse models. The findings support the company's continued translational work and its progression toward investigational new drug (IND)-enabling studies.

In the studies, Syntic Life's lead approach used defined reprogramming factors to partially restore the epigenetic markers that organize how cells function. Treated animals showed a measurable shift in markers of cellular age toward a younger state relative to untreated controls, while cells retained their original identity. No adverse safety signals were observed at the doses tested.

“Aging is the single largest modifiable risk factor for most chronic disease, and these results add to the growing evidence that it can be addressed at its root. Seeing aged cells move measurably toward a younger state — without losing what makes each cell what it is — is exactly the signal we hoped to find at this stage. It gives us the confidence to push this science forward with discipline.”

Targeting the root biology of aging

As cells age, the DNA sequence itself stays largely unchanged, but the epigenetic code that controls which genes are switched on or off becomes increasingly disorganized. These epigenetic changes are implicated across a wide range of age-related conditions. A growing body of research suggests that partially restoring this layer of biology can return cells toward a younger, healthier state — addressing the root biology of age-related disease rather than its symptoms alone.

Syntic Life's platform is built around this single, powerful mechanism. Because the same core approach — cellular rejuvenation through epigenetic restoration — can in principle be directed at many tissues, the company is developing it as a modular platform capable of supporting multiple organ-specific programs over time. Each future program would represent a distinct drug product, while sharing the same underlying biology.

What the studies showed

Across the reported studies, Syntic Life observed that its lead approach:

• Restored markers of cellular age toward a younger state relative to untreated controls;
• Preserved cell identity, with treated cells maintaining their original type and function; and
• Produced no adverse safety signals at the doses tested.

The company noted that these results were obtained in mouse models and that, as with all early-stage research, findings in animals may not predict outcomes in humans. The therapies remain investigational and have not been evaluated or approved by any regulatory authority.

What comes next

Syntic Life's current work is focused on the preclinical studies required to move this science toward the clinic with rigor and reproducibility. Near-term priorities include characterizing the durability of the rejuvenation effect, expanding safety and biodistribution profiling, and advancing the lead program toward IND-enabling studies.

“Our job now is to be rigorous. That means understanding how long the effect lasts, where it acts, and how it behaves across conditions — the questions that determine whether a promising biological result can become a real therapy. We're approaching that work with the seriousness it deserves.”

Syntic Life's research is supported by an AI discovery platform built by its sister company, Syntic AI, which helps identify and prioritize therapeutic targets before they reach the bench.

About Syntic Life

Syntic Life is a biotechnology company developing gene therapies that target the underlying biology of aging. By partially restoring the epigenetic markers that organize how cells work, the company aims to renew many tissues and address age-related conditions at their source. Syntic Life is headquartered in the United States, with labs in Rotan, China, and India. Learn more at syntic.life.

Media contact